FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195990721> ?p ?o ?g. }

• W3195990721 endingPage "1162" @default.
• W3195990721 startingPage "1156" @default.
• W3195990721 abstract "Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range = 14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI] = 82%-88%) overall and 90% (95% CI = 87%-92%) among adults without immunocompromising conditions. VE against COVID-19- associated hospitalization was 86% (95% CI = 82%-90%) 2-12 weeks and 84% (95% CI = 77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination." @default.
• W3195990721 created "2021-08-30" @default.
• W3195990721 creator A5000601543 @default.
• W3195990721 creator A5004725461 @default.
• W3195990721 creator A5006953289 @default.
• W3195990721 creator A5007966612 @default.
• W3195990721 creator A5009244008 @default.
• W3195990721 creator A5009475227 @default.
• W3195990721 creator A5009488288 @default.
• W3195990721 creator A5010334373 @default.
• W3195990721 creator A5010848966 @default.
• W3195990721 creator A5011965574 @default.
• W3195990721 creator A5012251011 @default.
• W3195990721 creator A5013669116 @default.
• W3195990721 creator A5013825896 @default.
• W3195990721 creator A5014347191 @default.
• W3195990721 creator A5016896001 @default.
• W3195990721 creator A5016911951 @default.
• W3195990721 creator A5017483954 @default.
• W3195990721 creator A5018827145 @default.
• W3195990721 creator A5020748777 @default.
• W3195990721 creator A5026626377 @default.
• W3195990721 creator A5027374619 @default.
• W3195990721 creator A5029459847 @default.
• W3195990721 creator A5029591195 @default.
• W3195990721 creator A5035286055 @default.
• W3195990721 creator A5035663660 @default.
• W3195990721 creator A5038114338 @default.
• W3195990721 creator A5039748898 @default.
• W3195990721 creator A5041342651 @default.
• W3195990721 creator A5042029720 @default.
• W3195990721 creator A5043282790 @default.
• W3195990721 creator A5046223220 @default.
• W3195990721 creator A5046325783 @default.
• W3195990721 creator A5047192284 @default.
• W3195990721 creator A5047332848 @default.
• W3195990721 creator A5049402910 @default.
• W3195990721 creator A5050001215 @default.
• W3195990721 creator A5051142049 @default.
• W3195990721 creator A5055712573 @default.
• W3195990721 creator A5056028181 @default.
• W3195990721 creator A5056287146 @default.
• W3195990721 creator A5056404361 @default.
• W3195990721 creator A5061113403 @default.
• W3195990721 creator A5061360456 @default.
• W3195990721 creator A5062950237 @default.
• W3195990721 creator A5066869339 @default.
• W3195990721 creator A5067861844 @default.
• W3195990721 creator A5067883398 @default.
• W3195990721 creator A5073974377 @default.
• W3195990721 creator A5074716051 @default.
• W3195990721 creator A5077236853 @default.
• W3195990721 creator A5079537228 @default.
• W3195990721 creator A5081844185 @default.
• W3195990721 creator A5083639360 @default.
• W3195990721 creator A5085016627 @default.
• W3195990721 creator A5087653992 @default.
• W3195990721 creator A5087672793 @default.
• W3195990721 creator A5087750390 @default.
• W3195990721 creator A5088431604 @default.
• W3195990721 creator A5090157461 @default.
• W3195990721 date "2021-08-27" @default.
• W3195990721 modified "2023-10-17" @default.
• W3195990721 title "Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021" @default.
• W3195990721 cites W2900791144 @default.
• W3195990721 cites W3122314944 @default.
• W3195990721 cites W3157661219 @default.
• W3195990721 cites W3158276912 @default.
• W3195990721 cites W3159689317 @default.
• W3195990721 cites W3160138987 @default.
• W3195990721 cites W3176239731 @default.
• W3195990721 cites W3177181935 @default.
• W3195990721 cites W3187850115 @default.
• W3195990721 doi "https://doi.org/10.15585/mmwr.mm7034e2" @default.
• W3195990721 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8389395" @default.
• W3195990721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34437524" @default.
• W3195990721 hasPublicationYear "2021" @default.
• W3195990721 type Work @default.
• W3195990721 sameAs 3195990721 @default.
• W3195990721 citedByCount "181" @default.
• W3195990721 countsByYear W31959907212021 @default.
• W3195990721 countsByYear W31959907212022 @default.
• W3195990721 countsByYear W31959907212023 @default.
• W3195990721 crossrefType "journal-article" @default.
• W3195990721 hasAuthorship W3195990721A5000601543 @default.
• W3195990721 hasAuthorship W3195990721A5004725461 @default.
• W3195990721 hasAuthorship W3195990721A5006953289 @default.
• W3195990721 hasAuthorship W3195990721A5007966612 @default.
• W3195990721 hasAuthorship W3195990721A5009244008 @default.
• W3195990721 hasAuthorship W3195990721A5009475227 @default.
• W3195990721 hasAuthorship W3195990721A5009488288 @default.
• W3195990721 hasAuthorship W3195990721A5010334373 @default.
• W3195990721 hasAuthorship W3195990721A5010848966 @default.
• W3195990721 hasAuthorship W3195990721A5011965574 @default.
• W3195990721 hasAuthorship W3195990721A5012251011 @default.
• W3195990721 hasAuthorship W3195990721A5013669116 @default.
• W3195990721 hasAuthorship W3195990721A5013825896 @default.
• W3195990721 hasAuthorship W3195990721A5014347191 @default.

• next